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There is some evidence to show a possible role of guanosine in the modulation of cellular function, in par-
ticular, in the neuronal system. However, nothing is known about the role of guanine in renal function.
The aim of the present work was to investigate the role of guanine on modulation of Na+-ATPase activity
in isolated basolateral membrane (BLM) of the renal cortex. Guanine inhibited the enzyme activity in a
dose-dependent manner with maximal effect (56%) obtained at 106 M. This effect was reversed by
DPCPX (8-cyclopentyl-1,3-dipropylxanthine), an antagonist of A1 receptors, but it was not changed by
108 M DMPX (3,7-dimethyl-1-propargylxanthine) or 108 M MRS (2,3-diethyl-4,5-dipropyl-6-phenyl-
pyridine-3-thiocarboxylate-5-carboxylate), antagonists of A2 and A3 receptors, respectively. Furthermore,
it was observed that guanine increased [c-35S]GTP-speciﬁc binding with the maximal effect observed at
106 M and this effect was abolished by 106 M GDPbS. The inhibitory effect of 106 M guanine on
Na+-ATPase activity was reversed by 106 M GDPbS, 106 M forskolin, 106 M pertussis toxin and
108 M cholera toxin. These results indicate that guanine binds to a DPCPX-sensitive receptor promoting
the activation of Gi protein and leading to a decrease in cAMP level and, consequently, inhibition of BLM
Na+-ATPase activity.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The importance of adenine nucleosides and nucleotides in
modulating cellular function through interaction with speciﬁc
receptors is well known [1]. In the last decades, the idea that
guanine-based nucleosides and nucleotides could also play an
important role as signaling molecules modulating the cellular
function has emerged. The molecular mechanism of guanosine
and the action of guanine-based nucleotides are not known. It
has been proposed that these compounds do not interact with clas-
sic purinergic receptors P1 and P2 types [2]. Traversa et al. [3] pro-
posed a speciﬁc binding site for guanosine in rat brain membranes
insensitive to adenine-based nucleosides and nucleotides. Further-
more, some evidence indicates that the effects of guanosine are
mediated either by adenosine secretion or due to its intracellular
metabolism [2].
It is known that guanine-based nucleotides released in the
extracellular medium generate guanosine, which is readily con-
verted into guanine by purine nucleoside phosphorylase [4].
However, the possible role of GUA in cellular function is poorlyes).
evier OA license.understood. For a long time it was believed that metabolites
formed from purine-based nucleoside metabolism do not affect
cellular function. Contrary to this view, it has been shown that
adenosine metabolites such as adenine trigger a cellular re-
sponse in different cell types such as renal and neuronal cells
[5,6]. Garozzo et al. [2] showed that guanine exerted marked
growth inhibition on the U87 glioma cell line similar to guano-
sine and GMP.
It has been shown that adenine nucleosides and nucleotides
play a critical role in renal function, in particular, in renal sodium
excretion [7,8]. We have shown that this effect of adenosine is
mediated, at least in part, by inhibition of proximal tubule (PT)
Na+-ATPase activity. We have also observed that adenine, an
end-product of adenosine metabolism, binds to an 8-cyclopentyl-
1,3-dipropylxanthine (DPCPX)-insensitive receptor in basolateral
membrane (BLM) inhibiting Na+-ATPase activity. However, noth-
ing is known about the role of guanine in renal function. The
aim of the present work was to investigate the role of guanine
on the modulation of Na+-ATPase activity in isolated BLM of PT.
Our results show that guanine inhibits Na+-ATPase activity
through a DPCPX-sensitive receptor that involves the activation
of Gi protein. These data open new perspectives on understanding
the role of guanine on the modulation of renal sodium excretion.
Fig. 1. Modulation of Na+-ATPase activity by purines. (A) Dose-dependent inhibi-
tion of Na+-ATPase activity induced by guanine (GUA). (B) Adenine and GUA have
similar effects on the enzyme activity. The results are expressed as mean ± SE.
⁄Statistically signiﬁcant compared with controls (p < 0.05, n = 8).
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Materials
[35S]Guanosine 5&prime;-O-thiotriphosphate (GTPcS; 1065 Ci
mmol1) was purchased from Amersham Biosciences, UK Limited.
[32P]Pi was obtained from the Institute of Energetic and Nuclear Re-
search, São Paulo, SP, Brazil. ATP, ouabain, furosemide, guanosine,
adenosine, dibutyryl-cAMP, guanosine 5&prime;-O-(2-thiodiphos-
phate) (GDPbS), GTPcS, ethylenediaminetetraacetic acid (EDTA),
N-2-hydroxyethylpiperazine N&prime;-2-ethanesulfonic acid (HEP
ES), tris(trishydroxy-methyl)-aminomethane (Tris) were purchased
from Sigma Chemical Co., St. Louis, MO, USA. Percoll was purchased
from Pharmacia Biotech, Uppsala, Sweden. DPCPX (8-cyclopentyl-
1,3-dipropylxanthine), DMPX (3,7-dimethyl-1-propargylxanthine)
and MRS 1523 (2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thio-
carboxylate-5-carboxylate)was purchased fromResearch Biochem-
icals International, Natick, MA, USA. All other reagents were of the
highest purity available. All solutionswere preparedwith deionized
glass-distilled water. [c-32P]ATP was prepared as previously de-
scribed [9].
Isolation of the BLM
Isolated BLM from renal cortex was obtained from adult pig kid-
ney using the Percoll gradient method [10]. The membrane prepa-
ration was diluted in 250 mM sucrose at a ﬁnal concentration of 5–
10 mg of protein ml1 and stored at +4 C. The speciﬁc activity of
the BLM marker, (Na+ + K+)ATPase activity, was enriched 8-fold
compared with that measured in kidney cortex homogenate. The
(Na+ + K+)ATPase activity in BLM was 169.8 ± 7.8 nmol Pi mg1
min1.
ATPase activity assay
ATPase activity was measured according to the method
described by Grubmeyer and Penefsky [11]. The composition of
the assay medium for the measurement of Na+-ATPase activity
(0.1 ml) was: 102 M MgCl2; 5  103 M ATP (speciﬁc activity of
approximately about 104 Bq/nmol ATP); 2  102 M HEPES–Tris
(pH 7.0); 9  102 M NaCl; 103 M ouabain. The reaction was per-
formed as described in a previous work [12]. The [32P]Pi released
was measured in an aliquot of the supernatant obtained after cen-
trifugation of the charcoal suspension for 5 min at 2000 rpm in a
clinical centrifuge (Fanem, São Paulo, Brazil). Spontaneous hydro-
lysis of [c-32P]ATP represents less than 5% of the speciﬁc hydroly-
sis. The Na+-ATPase activity was calculated from the difference
between the [32P]Pi released in the absence and in the presence
of 2  103 M furosemide. Protein concentrations were determined
by the Folin phenol method [13] using bovine serum albumin as a
standard. Each experiment was performed on at least four inde-
pendent preparations of BLM.
[35S]GTPcS binding assay
The [35S]GTPcS binding assay was carried out using isolated
BLM as described by Lazareno [14] with some modiﬁcations. The
composition of the reaction medium (0.05 ml) was: 100 mM NaCl,
10 mM MgCl2, 20 mM HEPES–Tris (pH 7.0) and 5 nM [35S]GTPcS
(1065 Ci mmol1). The reaction was started by addition of isolated
BLM (1 mg ml1). After 1 min at 37 C, the reaction was stopped by
addition of 5 ml of ice-cold buffer (100 mM NaCl, 10 mM MgCl2,
20 mM HEPES–Tris (pH 7.0)). The content of each tube was imme-
diately ﬁltered and washed twice with 5 ml of ice-cold buffer
through a glass ﬁber ﬁlter (MFS Advantec Inc. GB140, 25 mmdiameter) under a vacuum. The radioactivity in the ﬁlters was
measured by liquid scintillation counting (Packard Tri-Carb 2100
TR). Speciﬁc binding was determined as the difference between
the binding of [35S]GTPcS in the absence and in the presence of
1 mM GTP.
Statistical analysis
The data were analyzed by two-way analysis of variance (ANO-
VA), considering the treatments as factors. The signiﬁcance of the
differences was veriﬁed by the Bonferroni test.
Results and discussion
Guanine modulates Na+-ATPase activity in the isolated BLM of PT
In the present work, isolated BLM of PT from pig kidney was
used. This preparation is useful to avoid the possible effect of guan-
ine mediated by its metabolism in the intracellular compartment
[2]. Furthermore, it has been shown that this preparation has dif-
ferent elements of signaling cascades involved in the rapid modu-
lation of Na+-ATPase activity by hormones and autacoids [15–18].
Therefore, it is a good model to study the modulation of Na+-ATP-
ase activity by extracellular messenger that triggers membrane
signaling pathways.
Initially the possible effect of guanine on BLM Na+-ATPase activ-
ity was evaluated. Incubation of isolated BLM with guanine for
10 min reduced the Na+-ATPase activity in a dose-dependent
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Under these conditions, the enzyme activity decreased from 23
(control) to 9.6 nmol Pi mg1 min1, corresponding to an inhibition
of 58%. At a concentration as low as 1010 M, guanine had already
induced a signiﬁcant inhibitory effect on the enzyme activity.
In recent years, our group has studied the role of adenine, an-
other purine base, in the modulation of the active sodium trans-
porters in PT such as Na+-ATPase [5]. In Fig. 1B we compared the
effects of adenine and guanine, at the same concentration
(106 M), on BLM Na+-ATPase activity. The maximal inhibitory ef-
fects of guanine and adenine were similar and nonadditive. These
data suggest that guanine and adenine share a similar pathway.
The molecular mechanism involved in the effect of adenine on
BLM Na+-ATPase activity has been determined in previous work
[5]. We showed that adenine is not modiﬁed by DPCPX, di-
methyl-1-propargylxanthine (DMPX), and MRS, antagonists of A1,
A2 and A3 receptors [5]. However, little is known about the possible
mechanism of action of guanine. Then, in the next group of exper-
iments we tested the modulation on the effect of guanine on the
enzyme activity by these antagonists.
The inhibitory effect of guanine was reversed by DPCPX in a
dose–response manner with complete reversion observed at 108
M (Fig. 2A). On the other hand, 108 M DMPX and 108 M MRS didFig. 2. DPCPX (108 M), the A1 receptor-selective antagonist, blocks the inhibitory
effect of GUA (106 M) on Na+-ATPase activity. (A) Dose-dependent effect of DPCPX
on the inhibitory effect of guanine (GUA) on Na+-ATPase activity. (B) DMPX and
MRS, A2 and A3 receptor-selective antagonists, respectively, did not affect the
inhibitory effect of GUA on Na+-ATPase activity. The results are expressed as
mean ± SE. Statistically signiﬁcant compared with ⁄controls or #enzyme activity in
the presence of 106 M GUA (p < 0.05, n = 6).not change the inhibitory effect of guanine on the enzyme activity
(Fig. 2B). The addition of these antagonists in isolation did not
change the enzyme activity. These results together with those ob-
tained in a previous paper show that guanine and adenine inhibit
the enzyme activity through different receptors.
So far these data show that the nucleobase guanine binds to
DPCPX-sensitive receptor and promotes the inhibition of BLM
Na+-ATPase activity. Because it is well known that a DPCPX-sensi-
tive receptor is associated with G proteins [19], we investigated the
involvement of heterotrimeric G protein.
The inhibitory effect induced by guanine on Na+-ATPase activity
involves a Gi protein-coupled receptor
The G protein activity was determined by an increase in
[35S]GTPcS-speciﬁc binding in isolated BLM. We observed that
guanine induced a dose-dependent increase in [c-35S]GTP-speciﬁc
binding with the maximal effect observed at 106 M (Fig. 3A). The
guanine-induced [35S]GTPcS binding at 106M was 62.8 ± 5.6 fmol
mg1. Under our experimental conditions, non-speciﬁc binding is
deﬁned as binding in the presence of 1 mM GTP, which was less
than 10% of the total binding. In addition we observed that
106 M GDPbS, a speciﬁc inhibitor of GTP binding in G protein,
completely blocked the guanine-induced increase in [35S]GTPcS-
speciﬁc binding (Fig. 3B). These data agree with the observation
that isolated BLM of PT has functional heterotrimeric G proteins
such as Gs, Gi and Gq that could be activated by G protein-coupled
receptors [8,20,21].
To correlate the effect of guanine on [35S]GTPcS-speciﬁc binding
and Na+-ATPase activity we measured the enzyme activity in the
presence of 106 M guanine and 106 M GDPbS (Fig. 3C). GDPbS
completely reversed the inhibitory effect of guanine on the enzyme
activity. The addition of GDPbS did not change the enzyme activity
[22]. Furthermore, we observed that 1 lg/ml pertussis toxin (PTX),
which uncouples Gi proteins from their receptors, also abolished
the inhibitory effect of guanine on Na+-ATPase activity (Fig. 4). It
is well known that Gi protein decreases the production of cAMP
due to inhibition of adenylyl cyclase. We observed that 106 M for-
skolin (FSK) and 108 M cholera toxin (CTX), activators of adenylyl
cyclase, abolished the inhibitory effect of guanine on the enzyme
activity (Fig. 4). The addition of either 106 M forskolin (FSK) or
108 M cholera toxin (CTX) increased the enzyme activity as
shown in a previous work [8]. The observation that DPCPX abol-
ished the guanine effect rules out the possible allosteric effect of
guanine on the Gi protein or adenylyl cyclase.
Based on the results, we postulate that guanine binds to a
DPCPX-sensitive receptor promoting the activation of Gi protein
leading to a decrease in the cAMP level and, consequently, the inhi-
bition of BLM Na+-ATPase activity. These ﬁndings are in accordance
with our previous work that shows the correlation between Na+-
ATPase activity and the basal level of cAMP [23]. Stimulation of
the adenylyl cyclase/PKA pathway is related to an increase in
Na+-ATPase activity [8] and attenuation of the basal cAMP level
by depressing adenylyl cyclase activity via Gi protein reduces en-
zyme activity [5]. Furthermore, it was observed that all the signal-
ing pathway constituents involved in the Gi protein/adenylyl
cyclase/PKA signaling pathway are associated with the plasma
membrane, as previously reported [8,15,20,23].
Most studies indicate that the effects of guanosine and guanine
depend on their uptake and metabolism inside the cell to form GTP
[2]. It was shown that the effect of guanosine on proliferation of rat
astrocytes is mediated via complex mechanisms involving secre-
tion of adenosine to the extracellular compartment [24]. Both pos-
sibilities can be ruled out because we used an isolated BLM
preparation that does not contain intracellular components and
does not secrete adenosine. Our results show that the effect of
Fig. 3. Involvement of a G protein-coupled receptor in the inhibitory effect induced
by adenine on Na+-ATPase activity. (A) Guanine-induced dose-dependent increase
in [35S]GTPcS binding to isolated BLM. [35S]GTPcS-speciﬁc binding was obtained in
the presence of 1 mM GTP. (B) Guanine-induced speciﬁc binding of [35S]GTPcS is
blocked by 106 M GDPbS, a non-selective G protein inhibitor. When indicated,
106 M adenine was added. (C) GDPbS blocks the inhibitory effect of GUA on Na+-
ATPase activity. The results are expressed as absolute values ± SE. ⁄Statistically
signiﬁcant compared with controls (p < 0.05) (n = 12).
Fig. 4. Guanine-induced inhibition of Na+-ATPase activity involves suppression of
basal adenylyl cyclase activity by the Gi protein. The guanine-induced effect is
mediated by the pertussis toxin-sensitive Gi protein. PTX (1 lg/ml), FSK (106 M) or
CTX (108 M) were added when indicated. The results are expressed as absolute
values ± SE. ⁄Statistically signiﬁcant compared with controls (p < 0.05) (n = 7).
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to Gi protein. The only evidence, at least to our knowledge, that
guanine binds to a speciﬁc site was obtained by Traversa et al.
[3]. It was observed that guanine displaces [3H]guanosine-speciﬁc
binding in rat brain membranes [3]. It was also shown that this
[3H]guanosine-speciﬁc binding triggers activation of Gi protein.
Our data reinforce the hypothesis for a Gi protein-coupled receptor
as a mediator of guanine-induced effects in the central nervous
system as well as in the kidney PT.
The nature of the possible receptor involved in the effect of
guanine on cellular function is still an open matter. It has been
proposed that guanine-based compounds do not bind to adenosinereceptors [25]. In the present work, we have shown that guanine
acts through a DPCPX-sensitive receptor. DPCPX has been
described as a speciﬁc A1 receptor antagonist, therefore our results
could indicate that guanine binds to the A1 receptor. In agreement
with this, we observed that adenosine, via the A1 receptor, inhibits
BLM Na+-ATPase activity through activation of Gi protein [15].
However, we cannot rule out the possibility that the effect of
DPCPX is due to its action on a different receptor activated by
guanine. In rat brain membranes, contrary to guanine, adenosine,
a ligand of the A1 receptor, did not have affect on [3H]guanosine-
speciﬁc binding. The differences found in isolated BLM of renal
PT cells and rat brain membranes could indicate that the guanine
binding site in rat brain membranes is different from that observed
in the present work. In agreement with this hypothesis, it was
observed that the concentration of guanine that inhibits BLM
Na+-ATPase activity is at least 1000 times lower than the concen-
tration necessary to promote the total displacement of [3H]guano-
sine-speciﬁc binding in rat brain membranes [3]. Kelly et al. (2001)
observed that the concentration of guanosine in the plasma of
Sprague–Dawley rats is about 1 lM and it is increased about three
times under ischemic conditions [26]. It is known that guanosine is
converted into guanine by purine nucleoside phosphorylase [4].
During chemical anoxia in vitro and renal ischemia, a remarkable
decrease in cellular GTP levels occurs [27]. When GTP is depleted,
the concentration of guanine tends to increase. Guanine could be a
transporter to the extracellular side through speciﬁc transporters
expressed in PT cells [28]. Another possibility for the increase in
the extracellular level of guanine could be due to rupture of the
PT cells observed in ischemic conditions or GTP metabolism by
ecto-enzymes [27]. Recently, Garozzo et al. [2] showed that guan-
ine exerted marked growth inhibition on the U87 glioma cell line
with maximal effect observed at 103 M. The GI50 was 140 ±
10.2 lM. These concentrations are higher than the concentration
used in the present study indicating that the effects of guanine ob-
served in the present study could have physiologic and pathologic
signiﬁcance. An increase in renal sodium excretion during short
periods of ischemia is observed. However, the molecular mecha-
nism mediating this increase has not yet been determined. Thus,
our data suggest a potential role for guanine in PT sodium reab-
sorption throughmodulation of Na+-ATPase. In support of this idea,
we have shown correlation between this enzyme activity and renal
sodium excretion.
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